Jco Precision Oncology
Overview
Jco Precision Oncology is a scientific journal, published since 2017 in English. The journal's country of origin is United States and its primary focus area is oncology.
Details
Details
Abbr.
JCO Precis Oncol
Start
2017
End
Continuing
e-ISSN
2473-4284
Country
United States
Language
English
Specialty
Oncology
Metrics
Metrics
h-index / Ranks: 7562
48
SJR / Ranks: 976
2249
CiteScore / Ranks: 2159
8.20
JIF / Ranks: 1820
4.6
Recent Articles
41.
Yu J, He A, Ouf M, Mehta R, Anaya D, Denbo J, et al.
JCO Precis Oncol
. 2025 Jan;
9():e2400443.
PMID: 39772829
Purpose: This study aimed to assess (1) the prognostic value of circulating tumor DNA (ctDNA) and (2) the ability of ctDNA to detect recurrence compared with standard surveillance in curatively...
42.
Sakatani T, Sumiyoshi T, Kita Y, Takada H, Nakamura K, Hamada A, et al.
JCO Precis Oncol
. 2025 Jan;
9:e2400472.
PMID: 39761498
Purpose: Circulating tumor DNA (ctDNA) analysis is an alternative to tissue biopsy for genotyping in various cancers. We aimed to establish a plasma ctDNA sequencing assay, then evaluate its clinical...
43.
Ma C, Shulman D, Al-Sayegh H, Dubois S, London W
JCO Precis Oncol
. 2024 Dec;
8():e2400360.
PMID: 39715485
Purpose: Novel therapies targeting specific genomic alterations are a promising treatment approach for relapsed/refractory cancer. Patients with specific alterations may be more likely to respond. Trial designs should maximize opportunities...
44.
Liu Y, Sia T, Varice N, Wu M, Byrne M, Khurram A, et al.
JCO Precis Oncol
. 2024 Dec;
8:e2400525.
PMID: 39715484
Purpose: Although germline genetic testing (GT) is recommended for all patients with ovarian cancer (OC) and some patients with endometrial cancer (EC), uptake remains low with multiple barriers. Our center...
45.
Ozay Z, Hage Chehade C, Agarwal N, Swami U
JCO Precis Oncol
. 2024 Dec;
8:e2400766.
PMID: 39693590
No abstract available.
46.
Basu A, Au C, Kommalapati A, Kandala H, Sudhaman S, Mahmood T, et al.
JCO Precis Oncol
. 2024 Dec;
8:e2400667.
PMID: 39693589
Purpose: Tumor-informed circulating tumor DNA (ctDNA) has shown promise as a biomarker for treatment response monitoring (TRM) in a variety of tumor types, with the potential to improve clinical outcomes....
47.
Morris L, Pappas L, Pandey A, Singh H, Klempner S, Caughey B
JCO Precis Oncol
. 2024 Dec;
8:e2400547.
PMID: 39693588
No abstract available.
48.
Zauderer M, Jegede O, Jackman D, Zwiebel J, Gray R, Wang V, et al.
JCO Precis Oncol
. 2024 Dec;
8:e2400327.
PMID: 39693587
Purpose: The NCI-MATCH trial assigned patients with solid tumors, lymphomas, or multiple myeloma to targeted therapies on the basis of identified genetic alterations from tumor biopsies. In preclinical models, ()-inactivated...
49.
Kirkendoll C, Mansour R, Gaddam S
JCO Precis Oncol
. 2024 Dec;
8:e2400401.
PMID: 39666931
No abstract available.
50.
Shickh S, Mighton C, Clausen M, Sam J, Hirjikaka D, Reble E, et al.
JCO Precis Oncol
. 2024 Dec;
8:e2400407.
PMID: 39666930
Purpose: Genomic sequencing (GS) is increasingly used to improve diagnoses and inform targeted therapies. GS can also be used to identify the 10% of cancer patients with an underlying hereditary...